Session » (1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II
-
Abstract Number: 1155
Identification of Serum Biomarkers Associated with Muscle Damage Detected on MRI in Polymyositis/dermatomyositis
-
Abstract Number: 1156
Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong
-
Abstract Number: 1157
Experience of Pain in Adults with Idiopathic Inflammatory Myopathies, Myositis
-
Abstract Number: 1158
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
-
Abstract Number: 1159
Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients
-
Abstract Number: 1160
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
-
Abstract Number: 1161
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
-
Abstract Number: 1162
Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies
-
Abstract Number: 1163
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
-
Abstract Number: 1164
Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
-
Abstract Number: 1166
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
-
Abstract Number: 1168
Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
-
Abstract Number: 1169
All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China
-
Abstract Number: 1170
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
-
Abstract Number: 1171
Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
-
Abstract Number: 1173
Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
-
Abstract Number: 1174
Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review
-
Abstract Number: 1175
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
-
Abstract Number: 1176
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
-
Abstract Number: 1177
Anti-HMGCR Autoantibody Levels in the Follow-up of Statin-induced Immune-mediated Necrotizing Myopathy: Multicentric Study of 24 Patients
-
Abstract Number: 1178
Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter
-
Abstract Number: 1179
Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome
-
Abstract Number: 1180
Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality
-
Abstract Number: 1181
Real-World Myositis Antibody Frequency and Patient Awareness
-
Abstract Number: 1182
Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies